|
Onset and maintenance of testosterone suppression in four pivotal trials of subcutaneously administered leuprolide acetate formulated with in-situ forming polymeric delivery technology. |
|
|
Stock and Other Ownership Interests - Exelixis |
Honoraria - Astellas Pharma; Bayer; Genentech; Janssen; Medivation |
Consulting or Advisory Role - Tolmar |
Speakers' Bureau - Astellas Pharma; Bayer; Genentech; Janssen; Medivation |
|
|
|
Travel, Accommodations, Expenses - Tolmar |
|
|
|
Travel, Accommodations, Expenses - Tolmar |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Bayer; Bellicum Pharmaceuticals; Dendreon; Endocyte; Johnson & Johnson; Medivation; Oncogenex; Progenics (Inst); Sanofi; Tokai Pharmaceuticals |
Research Funding - Bayer (Inst); Dendreon (Inst); Endocyte (Inst); Innocrin Pharma (Inst); InVitae (Inst); Johnson & Johnson (Inst); Progenics (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bellicum Pharmaceuticals; Johnson & Johnson; Medivation; Oncogenex; Progenics; Sanofi; Tokai Pharmaceuticals |